Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2023 | Long-term outcomes and toxicities of ibrutinib in CLL

Alessandra Ferrajoli • 7 Sep 2023
SOHO 2023
Chronic Lymphocytic Leukemia Leukemia BTK inhibitors Ibrutinib

Alessandra Ferrajoli, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the long-term outcomes of patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib, highlighting the risk of hypertension and cardiovascular toxicity. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Alessandra Ferrajoli

0:59
Mitigating cardiological toxicities associated with BTKi in B-cell malignancies
Alessandra Ferrajoli • 11 Dec 2023
1:22
Does acalabrutinib increase the risk of hypertension in patients with CLL?
Alessandra Ferrajoli • 11 Dec 2023
1:22
The role of ibrutinib in CLL and important adverse events to consider with the use of this agent
Alessandra Ferrajoli • 7 Sep 2023
1:12
Insights into the optimal management of CLL: the importance of patient characteristics
Alessandra Ferrajoli • 7 Sep 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals